Acetaminophen Proposals Could Hit Firms Hard Via Sales And Costs
This article was originally published in The Tan Sheet
Executive Summary
Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk